The company's consolidated net profit jumped multifold to Rs 230 crore as compared to Rs 46 crore a year ago in the December ...

Background: The trivalent inactivated split-influenza vaccine, Fluarix TM has been available since 1992. Aim: To assess the safety and immunogenicity of the vaccine from studies in healthy adults ...

Sales of the influenza vaccine, Fluarix, rose 14%. Sales of Established vaccines improved 8%. During the quarter, GSK did not record any sales from the COVID-19 booster vaccine, which was co ...

We have reported here the results of studies of the immunogenicity and reactogenicity of this vaccine in patients at increased risk of severe influenza or developing influenza-related ...